| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2010: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2009: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
|
|---|
| Research Abstract |
CD19^+ cells from peripheral blood or bone marrow (BM) of MM patients were transplanted to NOD/Scid,IL-2Rγnull mice. However, MM disease did not develop in the recipient mice even in the transplants with highly expanded clonotypic CD19^+ B cells. On the other hand, in the SCID-rab model, CD38^<++> MM plasma cells, but not CD19^+ B cells, from MM patients engrafted and generated MM disease in rabbit BM that had been implanted subcutaneously in SCID mice. While CD138- BM cells, in which MM progenitors were reported to exist, generated MM disease in the SCID-rab model, the engrafting cells were CD38^<++>CD138^- plasma cells, not CD19^+ B cells. These results indicate that MM progenitor cells that can initiate and maintain MM disease are present in CD38^<++> plasma cells. We also found that CD48, a cell surface glycoprotein not previously associated with MM, is a promising candidate as a target antigen for antibody therapy against MM. One of the newly generated anti-CD48 mAbs significantly inhibited tumor growth in SCID mice inoculated with MM cells.
|
